1 of 1
Story summary
- Ozempic did not slow Alzheimer's progression after a two-year, 1,855-participant study.
- The study found no cognitive benefits for those with mild cognitive impairment or dementia.
- CEO Maziar Mike Doustdar expressed disappointment, saying, "This is not the outcome we had hoped for."
- Ozempic reduces body weight and shows promise for cardiovascular and kidney issues.
- Novo Nordisk plans to present results at conferences in December 2025 and March 2026; shares fell 6%.
